Skip to main content
SpringerLink
Log in

Choroidal Melanoma: Clinical Trials and What Have We Learned from Them

  • Chapter
  • First Online:
Intraocular Tumors

  • 508 Accesses

Abstract

Choroidal melanoma is the most common primary intraocular tumor but its incidence is only around 5 per million. In spite of the rarity of the tumor, well conducted clinical trials have significantly altered the management, improving the overall prognosis. This chapter highlights the key clinical trials that have brought a paradigm shift in the management of choroidal melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sargent DJ, Korn EL. Decade in review—clinical trials: shifting paradigms in cancer clinical trial design. Nat Rev Clin Oncol. 2014;11:625–6.

    CAS  PubMed  Google Scholar 

  2. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000–7.

    PubMed  Google Scholar 

  3. Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology. 2005;112(9):1599–607.

    PubMed  Google Scholar 

  4. Weis E, Shah CP, Lajous M, et al. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol. 2006;124(1):54–60.

    PubMed  Google Scholar 

  5. Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.

    PubMed  Google Scholar 

  7. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.

    PubMed  PubMed Central  Google Scholar 

  8. Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014;24(6):525–34.

    CAS  PubMed  Google Scholar 

  9. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1990;108:1268–73.

    Google Scholar 

  10. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS report no. 2. In: Franklin RM, editor. Proceedings of the symposium on retina and vitreous, New Orleans Academy of Ophthalmology. New York: Kugler Publications; 1993. p. 181–90.

    Google Scholar 

  11. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the collaborative ocular melanoma study. COMS report no. 3. Control Clin Trials. 1993;14:362–91.

    Google Scholar 

  12. Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol. 1997;115:886–93.

    Google Scholar 

  13. Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS report no. 5. Arch Ophthalmol. 1997;115:1537–44.

    Google Scholar 

  14. Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745–66.

    Google Scholar 

  15. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: findings from the Collaborative Ocular Melanoma Study. COMS report no. 7. Control Clin Trials. 2001;22:526–37.

    Google Scholar 

  16. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR. Clear cell differentiation in choroidal melanoma. COMS report no. 8. Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115:894–8.

    CAS  PubMed  Google Scholar 

  17. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998;125:767–78.

    Google Scholar 

  18. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125:779–96.

    Google Scholar 

  19. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. III. Local complications and observations following enucleation. COMS Report No. 11. Am J Ophthalmol. 1998;126:362–72.

    Google Scholar 

  20. Collaborative Ocular Melanoma Study Group, et al. J Ophthalmic Nurs Technol. 1999;18(4):143–9, Part II, 18(5):219-232

    Google Scholar 

  21. Collaborative Ocular Melanoma Study Group. Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study. COMS report no. 13. Ophthalmic Epidemiol. 2002;9:11–27.

    Google Scholar 

  22. Collaborative Ocular Melanoma Study Group. Cause-specific mortality coding: methods in the Collaborative Ocular Melanoma Study. COMS report no. 14. Control Clin Trials. 2001;22:248–62.

    Google Scholar 

  23. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report no. 15. Arch Ophthalmol. 2001;119:670–6.

    Google Scholar 

  24. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology. 2001;108(2):348–66.

    Google Scholar 

  25. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. II. Characteristics of patients enrolled and not enrolled. COMS report no. 17. Arch Ophthalmol. 2001;119:951–65.

    Google Scholar 

  26. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119:969–82.

    Google Scholar 

  27. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;198:2197–206.

    Google Scholar 

  28. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997. Findings from patients evaluated at Collaborative Ocular Melanoma Study centers. COMS report no. 20. Arch Ophthalmol. 2003;121:1156–62.

    Google Scholar 

  29. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histologic measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report no. 21. Arch Opthalmol. 2003;121:1163–71.

    Google Scholar 

  30. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS report no. 22. Ophthalmology. 2004;111:996–76.

    Google Scholar 

  31. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, et al. Screening for metastasis from choroidal melanoma: experience of the Collaborative Ocular Melanoma Study. Collaborative Ocular Melanoma Study report no. 23. Am J Clin Oncol. 2004;22:2438–44.

    Google Scholar 

  32. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. IV. Ten-year mortality findings and prognostic factors. COMS report no. 24. Am J Ophthalmol. 2004;138:936–51.

    Google Scholar 

  33. Collaborative Ocular Melanoma Study Group. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma. COMS report no. 25. Arch Ophthalmol. 2005;123:601–4.

    Google Scholar 

  34. Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005;123:1639–43.

    Google Scholar 

  35. Collaborative Ocular Melanoma Study Group. Incidence of cataract and outcomes after cataract surgery in the first 5 years after 125I brachytherapy in the COMS. COMS report no. 27. Ophthalmology. 2007;114:1363.

    Google Scholar 

  36. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors. COMS report no. 28. Arch Ophthalmol. 2006;124:1684–93.

    Google Scholar 

  37. Collaborative Ocular Melanoma Study -- Quality of Life Study Group. Quality of life after iodine 125 brachytherapy versus enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study prospective study. COMS-QOLS report no. 3. Arch Ophthalmol. 2006;124:226–38.

    Google Scholar 

  38. Mashayekhi A, Shields CL, Rishi P, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology. 2015;122(3):600–9.

    PubMed  Google Scholar 

  39. Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology. 2011;118(2):402–7.

    PubMed  Google Scholar 

  40. Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65(3):780–7.

    PubMed  Google Scholar 

  41. Bechrakis NE, Petousis V, Willerding G, et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol. 2010;94(4):460–6.

    PubMed  Google Scholar 

  42. Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–75.

    PubMed  Google Scholar 

  43. Singh AD, Medina CA, Singh N, et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62.

    PubMed  Google Scholar 

  44. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–31. Epub 2007 Aug 27

    PubMed  Google Scholar 

  45. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.

    PubMed  PubMed Central  Google Scholar 

  46. Walter SD, Chao DL, Feuer W, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134:734–40.

    PubMed  PubMed Central  Google Scholar 

  47. Mruthyunjaya P, Seider MI, Stinnett S, Schefler A, Ocular Oncology Study Consortium. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. Ophthalmology. 2017;124:1532–9.

    PubMed  Google Scholar 

  48. Gezgin G, Luk SJ, Cao J, et al. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol. 2017;135(6):541–9.

    PubMed  PubMed Central  Google Scholar 

  49. Decatur CL, Ong E, Garg N, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.

    PubMed  PubMed Central  Google Scholar 

  50. Kivelä TT, Piperno-Neumann S, Desjardins L, et al. Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group. Am J Ophthalmol. 2016;168:217–26.

    PubMed  Google Scholar 

  51. Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol. 2014;1:54–62.

    PubMed  PubMed Central  Google Scholar 

  52. Goh AY, Layton CJ. Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. Clin Exp Ophthalmol. 2016;44(6):509–19.

    PubMed  Google Scholar 

  53. Buder K, Gesierich A, Gelbrich G, et al. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013;2(5):674–86.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

No financial interest associated with manuscript

  • “This work was supported in part by an unrestricted institutional grant from Research to Prevent Blindness, NY, NY.”

Author information

Authors and Affiliations

  1. Kentucky Lions Eye Center, University of Louisville, Louisville, KY, USA

    Sidharth Puri & Aparna Ramasubramanian

Authors
  1. Sidharth Puri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aparna Ramasubramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aparna Ramasubramanian .

Editor information

Editors and Affiliations

  1. Sankara Nethralaya, Chennai, Tamil Nadu, India

    Vikas Khetan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Puri, S., Ramasubramanian, A. (2020). Choroidal Melanoma: Clinical Trials and What Have We Learned from Them. In: Khetan, V. (eds) Intraocular Tumors. Springer, Singapore. https://doi.org/10.1007/978-981-15-0395-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0395-5_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0394-8

  • Online ISBN: 978-981-15-0395-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation